| Contributors: |
Zambelli, A.; Cortesi, L.; Gaudio, M.; Arpino, G.; Bianchini, G.; Caruso, F.; Cinieri, S.; Curigliano, G.; Del Mastro, L.; De Placido, S.; Fabi, A.; Fortunato, L.; Generali, D.; Gennari, A.; Gori, S.; Grandi, G.; Guarneri, V.; Klinger, M.; Livi, L.; Marchiò, C.; Palumbo, I.; Panizza, P.; Pravettoni, G.; Pruneri, G.; Puglisi, F.; Sapino, A.; Tinterri, C.; Turchetti, D.; De Laurentiis, M. |
| Description: |
The introduction of PARP inhibitors has revolutionized the management and treatment of patients with pathogenic germline variants of BRCA1/2 who have developed breast cancer. The implementation of PARP inhibitors in clinical settings can be challenging due to their overlapping indications with other drugs, including both recently approved medications and those with proven efficacy. This study utilized the Delphi method to present the first Italian consensus regarding genetic testing, the use of PARP inhibitors in both early and metastatic settings, and strategies for managing the potential toxicity of these novel drugs. The Panel unanimously agreed on various issues, including the timing, techniques, and patient characteristics for BRCA1/2 genetic testing, and the appropriate placement of PARP inhibitors in the treatment algorithm for both early and advanced breast cancer. Nevertheless, some areas of divergence became evident, particularly regarding the use of axillary surgery for therapeutic purposes and the application of hormone replacement therapy in cases of bilateral mastectomy and risk-reducing salpingo-oophorectomy for patients treated for triple negative breast cancer. Additional research is needed in these particular domains to improve the care of patients with breast cancer who bear an increased genetic risk. |